-transparent.png){kind=logo}
Cultured endothelial cells derived from human umbilical veins or bovine aorta produce a potent inhibitor of platelet aggregation. The inhibitor is synthesized from sodium arachidonate or or prostaglandin endoperoxides by a microsomal enzyme system. Tranylcypromine, a specific antagonist of prostacyclin synthetase, suppresses production of the inhibitor by endothelial cells. The inhibitor, which is ether extractable, has been identified using a two-step thin-layer radiochromatographic procedure and a synthetic prostaglandin I2 standard. With this procedure, we have shown that human and bovine endothelial cells convert sodium [3H]arachidonate to radiolabeled prostaglandin I2 and 6-keto-prostaglandin F1alpha, as wellas prostaglandin E2. Thus, endothelial cells may be non-thrombogenic in vivo because they synthesize and release prostaglandin I2, a potent inhibitor of platelet aggregation.
B B Weksler, and
A J Marcus, and
E A Jaffe
December 1978,
British journal of pharmacology,
B B Weksler, and
A J Marcus, and
E A Jaffe
November 1979,
Wiener klinische Wochenschrift,
B B Weksler, and
A J Marcus, and
E A Jaffe
March 1981,
The Journal of clinical investigation,
B B Weksler, and
A J Marcus, and
E A Jaffe
February 1985,
Journal of applied physiology (Bethesda, Md. : 1985),
B B Weksler, and
A J Marcus, and
E A Jaffe
December 1986,
Biochemical pharmacology,
B B Weksler, and
A J Marcus, and
E A Jaffe
January 1980,
Canadian Medical Association journal,
B B Weksler, and
A J Marcus, and
E A Jaffe
May 1986,
Prostaglandins, leukotrienes, and medicine,
B B Weksler, and
A J Marcus, and
E A Jaffe
February 1990,
Thrombosis research,
B B Weksler, and
A J Marcus, and
E A Jaffe
February 1992,
Archives of biochemistry and biophysics,
B B Weksler, and
A J Marcus, and
E A Jaffe
February 1987,
Transplantation proceedings,
